170,000 bottles of apple juice recalled in Ohio, other states over toxic substance worry
The Watsonville, California-headquartered company announced the recall on March 18, citing "potential contamination with patulin," according to the U.S. Food and Drug Administration. The recall impacts 7,234 cases of apple juice, which contained four of its signature 10-ounce glass bottles per pack, with six packs per case, bringing the recall to 173,616 bottles.
USA TODAY contacted S Martinelli & Company on April 26 but has not received a response.
The FDA said the impacted cases of apple juice were distributed in 28 U.S. states: Alabama, Arizona, Arkansas, California, Connecticut, Delaware, Florida, Georgia, Illinois, Indiana, Iowa, Kansas, Kentucky, Louisiana, Michigan, Mississippi, Missouri, New Hampshire, New Jersey, New York, North Carolina, Ohio, Pennsylvania, South Carolina, Texas, Utah, Virginia and Wisconsin.
The affected apple juice was sold by stores in 10-ounce 'bulbous/round glass bottle(s)" with a "white metal screw top lid," per the FDA's enforcement report. The recalled bottles had a 'best by' date of Dec. 5, 2026, and a UPC number reading '0 41244 04102 2.'
The recall is listed as Class II, meaning the use of or exposure to the product "may cause temporary or medically reversible adverse health consequences."
The four-packs of apple juice are available in-store at Meijer and listed for sale online through Target, Amazon and other retailers.
Meijer has 53 stores in Ohio, according to the data scraping website ScrapeHero. Ohio is second only to Michigan (with 124) in the number of Meijer stores in the nation.
According to the World Health Organization, patulin is a poisonous substance often found in rotting apples and apple products.
For humans, the acute symptoms from consuming patulin include nausea, gastrointestinal disturbances and vomiting, the agency said. The pasteurization process cannot remove patulin from the affected product, the FDA says.
This article originally appeared on Cincinnati Enquirer: More than 170,000 bottles of Martinelli's Apple Juice recalled in Ohio, US
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
7 minutes ago
- Yahoo
Merging deep tech and biomedical science expertise, ChronicleBio aims to accelerate breakthroughs for millions living with complex chronic conditions
New venture harnesses multi-omic data and AI to develop the largest platform on complex chronic illnesses to drive breakthroughs in POTS, ME/CFS, Long COVID, and other neuroimmune disorders SAN FRANCISCO, Aug. 5, 2025 /PRNewswire/ -- ChronicleBio, a techbio startup focused on radically accelerating insights on neuroimmune disorders, officially launched Tuesday with a bold mission: to build the world's richest, AI-ready data platform for historically overlooked conditions like POTS, ME/CFS, Long COVID, and other complex chronic conditions. ChronicleBio is uniquely led by a founding team that unites elite tech, healthcare, and life sciences: Fidji Simo (Co-founder), current CEO of Instacart and the incoming CEO of OpenAI's applications division, brings deep expertise in consumer-scale technology, product innovation, and health systems transformation. Rohit Gupta (Co-founder & CEO), a biobanking and precision medicine leader who previously oversaw centers at Stanford and UCSF, is the leading scientific and strategic force behind ChronicleBio. Rishi Reddy (Co-founder & Executive Chairman), of Tarsadia Investments, brings an entrepreneurial and venture-backed perspective and a track record in health and life sciences investing. Together, they are tackling a critical gap in biomedical research. ChronicleBio is creating a scalable, ethically driven data ecosystem, integrating clinical, molecular, biospecimen, and patient-reported insights to drive biomarker discovery, patient stratification, and precision therapeutic development. "Entire communities of patients have been ignored for too long, not because their conditions aren't debilitating and prevalent, but because the systems weren't built to understand them," said Fidji Simo, co-founder of ChronicleBio. "ChronicleBio is developing a future where patients can enlist in research, and where the data we collect from them goes directly towards better diagnostics and therapeutics. By building these critical missing datasets and leveraging the massive advances in AI, we aim to accelerate the path to cures." These complex chronic conditions impact nearly 300 million people worldwide, but remain woefully understudied, leaving patients hopeless and without meaningful treatments. It's a disease space desperate for data, and ChronicleBio is offering the scalable solutions to provide it. "Neuroimmune disorders remain some of the most poorly understood in medicine and not for lack of interest, but because the underlying data simply doesn't exist at the scale or structure required for serious breakthroughs," said Rohit Gupta, co-founder and CEO of ChronicleBio. "We're empowering patients and clinicians to get involved in this effort to grow our research-grade biobank and AI-ready data platform so we can close that gap and provide the tools to finally interrogate these diseases with scientific rigor and precision, bringing an end to complex chronic conditions." ChronicleBio partners directly with patients, clinics, and research collaborators to generate longitudinal, multi-modal datasets, including genomics, immune profiling, and real-world outcomes designed for exploration and clinical trial readiness. Its platform is already being used in multiple high-integrity clinics in the U.S. and India, as well as through research collaborations with thousands of patients contributing data and biosamples. "We're creating an ecosystem with global reach, designed not just to generate data, but to fundamentally shift how we discover, develop, and deliver treatments at scale. The opportunity for impact—scientifically, medically, and societally—is enormous," said Rishi Reddy, co-founder and Executive Chairman of ChronicleBio. "We're building the foundational infrastructure for a massive medical need that has been hiding in plain sight." ChronicleBio's founding vision isn't just ambitious. It's personal. Both Simo and Reddy have been diagnosed with at least one of the very conditions the company is focused on researching. Gupta's family also suffers from neuroimmune disorders. The group's world-class expertise is outshined only by its heartfelt determination to rewrite the scientific narrative for the millions of patients overlooked by traditional research and transform lived experience into actionable discovery. ChronicleBio's approach includes: A global biobank platform collecting and connecting data on neuroimmune illnesses A proprietary, AI-ready data engine designed to integrate multi-omic, clinical, and real-world evidence Strategic partnerships with clinics, research consortia, and biotech sponsors looking to unlock hard-to-crack therapeutic areas A decentralized clinical trial network accelerating drug development through real-world access to patients and clinicians For more information, visit or follow ChronicleBio on LinkedIn, X, Instagram, and Facebook. Media Contact:media@ View original content to download multimedia: SOURCE ChronicleBio Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Entrepreneur
9 minutes ago
- Entrepreneur
ChatGPT Says to Take a Break, Adds Mental Health Features
As ChatGPT continues to surge in popularity (the company disclosed on Monday that daily user messages exceeded three billion), OpenAI is urging users to cultivate healthier relationships with the AI chatbot. Beginning this week, ChatGPT sessions will now tell users to take breaks with reminders that interrupt lengthy sessions with the bot, the company announced in a blog post. The reminders will appear as pop-ups, and how often they will appear has not been announced. OpenAI's sample pop-up shows that the text of the pop-up will appear as "Just checking in" with the subtext "You've been chatting a while — is this a good time for a break?" Users will have to select "Keep chatting" to continue talking to ChatGPT. Related: ChatGPT's New Update Can Create PowerPoint Presentations and Excel Spreadsheets for You ChatGPT will also cease to provide users with direct answers to challenging questions, such as "Should I end my relationship?" Now, the chatbot will ask questions about the situation instead, so users can assess the pros and cons rather than get a direct answer. "ChatGPT is trained to respond with grounded honesty," OpenAI stated in the blog post. "There have been instances where our 4o model fell short in recognizing signs of delusion or emotional dependency." OpenAI further stated in the post that the company is "developing tools to better detect signs of mental or emotional distress" to equip ChatGPT with the tools to respond more appropriately to mental health crises. Related: ChatGPT Finally Gives Businesses What They've Been Asking For The mental health features arrive as ChatGPT reaches more users. OpenAI's Vice President and Head of the ChatGPT App, Nick Turley, said on Monday that they're "on track" to reach 700 million weekly users by the end of this week, a fourfold year-over-year growth, and up from 500 million users in March. This week, ChatGPT is on track to reach 700M weekly active users — up from 500M at the end of March and 4× since last year. Every day, people and teams are learning, creating, and solving harder problems. Big week ahead. Grateful to the team for making ChatGPT more useful and… — Nick Turley (@nickaturley) August 4, 2025 OpenAI has encountered problems with ChatGPT's responses before. In April, an update to the AI chatbot made it deliver overly flattering, out-of-touch responses, even to situations that required medical attention. For example, when one user told the chatbot that they stopped taking their medications and left their family because their loved ones made radio signals come from the walls, ChatGPT praised the user for "standing up" for themselves and listening to themselves "deep down, even when it's hard and even when others don't understand" instead of directing them to mental health professionals. Another user asked ChatGPT to assess his IQ, based on his spelling and grammar error-filled prompts, and the bot stated that the user came off "as unusually sharp" and said his IQ was "easily in the 130-145 range," above 98-99.7% of people. OpenAI stated in April in response that it had altered its training methods to steer ChatGPT away from flattery. Related: Saying 'Please' and 'Thank You' to ChatGPT Costs OpenAI 'Tens of Millions of Dollars' OpenAI raised $8.3 billion last week at a $300 billion valuation. Though OpenAI's user count is skyrocketing, it has yet to reach the heights achieved by Google. Google CEO Sundar Pichai said during a quarterly earnings call last month that Google's AI overviews, which are embedded in Google search, now reach over two billion monthly users in more than 200 countries. Meanwhile, Google's Gemini AI app, which provides AI answers to user prompts, now has more than 450 million active users.
Newsweek
10 minutes ago
- Newsweek
Baby Milk Recalled in 9 States, FDA Sets Risk Warning
Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources. Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content. A recent recall of human donor milk distributed across nine states has been classified as the second-highest risk level—of three—by food inspectors. The milk was voluntarily recalled by Columbus-based nonprofit Ohio Health Mother Milk Bank on July 14 after an inaccurate temperature reading from a thermometer on one pasteurization machine. The recall affects a total of 5,735 bottles of milk distributed in Minnesota, Missouri, New Jersey, North Carolina, Ohio, Pennsylvania, South Carolina, Vermont and West Virginia, the U.S. Food and Drug Administration said. FDA inspectors issued a Class II status on August 4, indicating a possibility of temporary or reversible health issues, or a remote chance of serious consequences. Newsweek contacted Ohio Health's media team via email on Tuesday. Stock photo shows a bottle of milk displayed in front of a sleeping baby. Stock photo shows a bottle of milk displayed in front of a sleeping baby. Getty Images Why It Matters The recall highlights recurring public health concerns surrounding safety and labeling of vital products intended for infants and medically vulnerable populations. FDA recall classifications are directly linked to the potential health consequences, with a Class II status indicating a possibility of temporary or medically reversible health issues, or only a remote chance of serious consequences, should consumers use the implicated product. What To Know Many mothers rely on donated or purchased human donor milk when not producing enough milk or when parents have adopted. It is also often given to premature or low birth weight infants. The recall affects: 4,006 units of OH MMB Human Donor Milk, 20.00 Cal/oz., 1.00 g/dl. Protein, packaged in 3 oz. plastic bottles And 1,729 units of OH MMB Human Donor Milk, 20.00 Cal/oz., 0.80 g/dl. Protein, packaged in 6 oz. plastic bottles The FDA said in its August 4 classification update that exact concentration of protein can vary. Affected customers in the nine states are advised to check any recently received milk bank products for recall status and contact the Ohio Health Mother Milk Bank or their state health department for further instruction. The U.S. Food and Drug Administration has three risk categories for food recalls. They are described on the agency's website as follows: "Class I—a situation in which there is a reasonable probability that the use of, or exposure to, a violative product will cause serious adverse health consequences or death. "Class II—a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote. "Class III—a situation in which use of, or exposure to, a violative product is not likely to cause adverse health consequences." What Happens Next The donor milk recall remains active and listed as ongoing by the FDA as of August 5. Subsequently, consumers in the affected states are urged not to use the recalled products and to consult with relevant health providers regarding possible exposure. If you are interested in donating your breast milk to Ohio Health, call (614) 566-0630 or email MilkBank@ to begin the donor screening process.
